We administered a mixed-method survey to 1,661 patients in a large health system to assess preferences toward antihypertensive use for dementia prevention. If a specific antihypertensive medication was shown to prevent or delay dementia, the vast majority (>90%) of respondents currently taking an antihypertensive reported that they would be willing to take that specific antihypertensive starting as early as mid-life. Concerns reported were potential side effects, lack of evidence of effectiveness, blood pressure being normal or low, and medication cost. Analysis of free-text responses revealed themes of concerns regarding evidence of effectiveness and health priorities.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Preventing Dementia and Cognitive Impairment; DowneyA, StroudC, LandisS, LeshnerAI, editors (2017) Preventing Cognitive Decline and Dementia: A Way Forward, The National Academies Press, Washington, DC.
3.
KehoePG (2018) The coming of age of the angiotensin hypothesis in Alzheimer’s disease: Progress toward disease prevention and treatment?J Alzheimers Dis61, 1443–1466.
4.
AshbyEL, MinersJS, KehoePG, LoveS (2016) Effects of hypertension and anti-hypertensive treatment on amyloid-beta (Aβ) plaque load and Aβ-synthesizing and Aβ-degrading enzymes in frontal cortex. J Alzheimers Dis50, 1191–1203.
WhartonW, GoldsteinFC, TanseyMG, BrownAL, TharwaniSD, VerbleDD, CintronA, KehoePG (2018) Rationale and design of the mechanistic potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial. J Alzheimers Dis61, 815–824.
7.
DacksPA, ArmstrongJJ, BrannanSK, CarmanAJ, GreenAM, KirkmanMS, KrakoffLR, KullerLH, LaunerLJ, LovestoneS, MerikleE, NeumannPJ, RockwoodK, ShinemanDW, StefanacciRG, VelentgasP, ViswanathanA, WhitmerRA, WilliamsonJD, FillitHM (2016) A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimers Res Ther8, 33.
8.
WalkerVM, DaviesNM, JonesT, KehoePG, MartinRM (2016) Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. BMJ Open6, e012044.
9.
DriscollDL, Appiah-YeboahA, SalibP, RupertDJ (2007) Merging qualitative and quantitative data in mixed methods research: How to and why not. Ecol Environ Anthropol3, Available at: http://digitalcommons.unl.edu/icwdmeea/18
10.
American Society on Aging Metlife Foundation (2006) Attitudes and Awareness of Brain Health Poll.American Society on Aging, San Francisco.
11.
SmithBJ, AliS, QuachH (2014) Public knowledge and beliefs about dementia risk reduction: A national survey of Australians. BMC Public Health14, 661.
12.
CreswellJW, ClarkVLP (2018) Designing and Conducting Mixed Methods Research. Sage Publications, Inc.
13.
HsiehHF, ShannonSE (2005) Three approaches to qualitative content analysis. Qual Health Res15, 1277–1288.
14.
Attride-StirlingJ (2001) Thematic networks: An analytic tool for qualitative research. Qual Res1, 385–405.
15.
GuoZ, FratiglioniL, ZhuL, FastbomJ, WinbladB, ViitanenM (1999) Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol56, 991–996.
16.
in’t VeldBA, RuitenbergA, HofmanA, StrickerBH, BretelerMM (2001) Antihypertensive drugs and incidence of dementia: The Rotterdam Study. Neurobiol Aging22, 407–412.
17.
KhachaturianAS, ZandiPP, LyketsosCG, HaydenKM, SkoogI, NortonMC, TschanzJT, MayerLS, Welsh-BohmerKA, BreitnerJC (2006) Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol63, 686–692.
18.
LiNC, LeeA, WhitmerRA, KivipeltoM, LawlerE, KazisLE, WolozinB (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ340, b5465.
19.
KehoePG, BlairPS, HowdenB,
ThomasDL,
MaloneIB,
HorwoodJ,
ClementC,
SelmanLE,
BaberH,
LaneA,
CoulthardE,
PassmoreAP,
FoxNC,
WilkinsonIB,
Ben-ShlomoY (2018) The rationale and design of the Reducing Pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) trial. J Alzheimers Dis61, 803–814.
20.
MarcumZA, HohlSD, GraySL, BartholdD, CranePK, LarsonEB (2019) Brain health and dementia prevention: A mixed-method analysis. Am J Health Behav43, 300–310.
21.
BarnesLL, BennettDA (2014) Alzheimer’s disease in African Americans: Risk factors and challenges for the future. Health Aff (Millwood)33, 580–586.
